Exploring Ruthenium-based organometallic inhibitors against Plasmodium Calcium Dependent Kinase 2 (PfCDPK2): a combined ensemble docking, QM paramterization and molecular dynamics study
Abstract
Recent advances in the metal-organic framework (MOF) have accelerated the discovery of novel metal-based anticancer, antibacterial and antimalarial compounds. This is substantiated by many serendipitously discovered metals (Ru, Rh, and Ir) based inhibitors that established the importance of metal inserted into the known organic scaffold. Conversely, it is possible to design novel bioactive compounds by mimicking hypervalent carbon atoms by transition metals. This process can be facilitated by computational drug discovery by treating metal center using optimized parameters that can be used for molecular docking and molecular dynamics simulations. Further, the method can be plugged with high computational power and refined algorithms to interpret chemical phenomena with atomic-level insights. In the present work, we have demonstrated an approach for parameterizing three organometallic ligands (FLL, E52, and staurosporine) using MCPB.py. In particular, we report that E52 and FLL have a better shape complimentary and affinity compared to staurosporine identified inhibitor (staurosporine) against Calcium-dependent protein kinases 2 (CDPK2). This study also revealed that a flexible approach (ensemble) outperforms for the given target with dynamic movements. The calculated MMPBSA energies for staurosporine, FLL and E52 were -66.461 {+/-} 2.192, -67.182 {+/-} 1.971 and -91.339 {+/-} 2.745 kcal/mol respectively.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting Plasmodium falciparum calcium dependent protein kinase-1: Computational modelling approach towards the discovery of antimalarial drug from medicinal herbs and clinically approved anti-malarial drugs pharmacophores
Temitope Isaac Adelusi, Taiwo Ooreoluwa Ojo, … Elijah Kolawole Oladipo·bioRxiv·Aug 22, 2022
- Drug repurposing approach for potential Pfmrk inhibitors as antimalarial agents: an In-silico analysis
- Development of novel anti-malarial from structurally diverse library of molecules, targeting plant-like Calcium Dependent Protein Kinase 1, a multistage growth regulator of P. falciparum
- Plasmodium falciparum Raf kinase inhibitor is a lipid binding protein that interacts with CDPK1 and regulates its activity in asexual blood stage.
M. Sharma, D. Krishnan, … A. Bansal·bioRxiv·Aug 23, 2023
- Biological evaluation of novel side chain containing CQTrICh-analogs as antimalarials and their development as PfCDPK1 kinase inhibitors
- A molecular dynamics investigation of CDK8/CycC and ligand binding: conformational flexibility and implication in drug discovery
W. Chen, Z. Tang, … C.-e. Chang·bioRxiv·Jul 28, 2017